Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Galecto (NASDAQ: GLTO) granted inducement equity awards on March 2, 2026 to four newly hired, non-executive employees, approved by its independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Galecto (NASDAQ: GLTO) granted inducement equity awards on March 2, 2026 to four newly hired, non-executive employees, approved by its independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The awards are non-qualified stock options to purchase an aggregate of 153,700 shares at an exercise price of $29.58 per share, with a 10-year term and vesting of 25% after one year then monthly over 36 months.

Argus Mar 4 session

+5.70% close to close Open Argus

Details

News Market Reaction – GLTO

In the Mar 4 session, GLTO gained 5.70%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with Gal...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with Galecto’s broader equity-driven story, where recent financings and strategic updates have supported significant moves from the $2.01 52‑week low toward levels well above the $12.48 200‑day MA. Inducement grants of 153,700 options at $29.58 per share modestly expand equity incentives. Investors would still have to weigh ongoing shelf usage and prior offerings when assessing how durable such strength might be over time.

Key Figures

Inducement options granted: 153,700 shares Exercise price: $29.58 per share Option term: 10 years +5 more

Inducement options granted

153,700 shares

Aggregate non-qualified stock options granted March 2, 2026

Exercise price

$29.58 per share

Strike price for inducement stock options

Option term

10 years

Duration of inducement stock options from grant date

Initial vesting

25%

Portion vesting on first anniversary of grant date

Remainder vesting period

36 months

Equal monthly vesting after first anniversary

Employees receiving grants

4 employees

Newly hired, non-executive employees

Current share price

$28.08

Price before publication, down 6.56% over 24h

52-week range

$2.01 – $38.33

Low and high prior to this news

Historical Context

5 past events · Latest: Mar 02

5 events

1. Mar 02

   Conference participation

   24h Move

   +1.6%

   Announcement of participation in Leerink Partners 2026 Global Healthcare Conference.

2. Feb 12

   Offering closing

   24h Move

   -3.0%

   Closing of $316.3M underwritten offering and full exercise of underwriters’ option.

3. Feb 10

   Offering pricing

   24h Move

   +1.3%

   Pricing of $275M underwritten public offering of common shares at $19.00.

4. Feb 10

   Offering announcement

   24h Move

   +1.3%

   Proposed underwritten offering of common and Series C non-voting preferred stock.

5. Jan 12

   Strategic update

   24h Move

   +6.4%

   Outline of 2026 clinical milestones and runway supported by a $285M PIPE.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, stock option agreement

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"consist of non-qualified stock options to purchase an aggregate of 153,700"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

stock option agreement technical

"subject to the terms and conditions of a stock option agreement."

A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by Galecto’s independent Compensation Committee and were made as material inducements to such individuals’ acceptance of employment with Galecto in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 153,700 shares of the Galecto’s common stock with a 10-year term and an exercise price of $29.58 per share. The options vest as to 25% on the first anniversary of the applicable grant date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Galecto, Inc. Inducement Plan, and the terms and conditions of a stock option agreement.

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.

Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Galecto (GLTO) announce on March 4, 2026?

Galecto granted non-qualified stock options totaling 153,700 shares as inducement awards to four new hires. According to Galecto, the options have a 10-year term, $29.58 exercise price, and standard time-based vesting starting after one year.

How do the Galecto (GLTO) inducement options vest and what is the exercise price?

The options vest 25% on the first anniversary, then monthly over the next 36 months. According to Galecto, the exercise price for the aggregate 153,700-share grant is $29.58 per share.

Why did Galecto (GLTO) use Nasdaq Listing Rule 5635(c)(4) for the March 2026 grants?

Galecto used Nasdaq Listing Rule 5635(c)(4) to classify the awards as material inducements for new employees. According to Galecto, the independent Compensation Committee approved the grants under that rule on March 2, 2026.

Who received the March 2, 2026 inducement grants from Galecto (GLTO)?

Four newly hired, non-executive employees received the inducement option awards. According to Galecto, these grants were made to induce acceptance of employment and were approved by the independent Compensation Committee.

What plan governs the terms of Galecto's (GLTO) March 2026 inducement option grants?

The inducement grants are governed by the 2022 Galecto Inducement Plan and individual stock option agreements. According to Galecto, the awards are subject to those plan terms and standard option agreement conditions.